Chan Yi X, Alfonso Helman, Chubb Stephen Anthony Paul, Fegan Peter Gerard, Hankey Graeme J, Golledge Jonathan, Flicker Leon, Yeap Bu B
School of Medicine and Pharmacology, University of Western Australia, Perth, WA, Australia.
Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, WA, Australia.
Clin Endocrinol (Oxf). 2017 Feb;86(2):278-285. doi: 10.1111/cen.13271. Epub 2016 Nov 28.
Thyroid hormones regulate cellular survival and metabolism; however, their association with cancer incidence and death has not been well explored.
Our aim was to examine the relationship between thyrotropin (TSH) and free thyroxine (FT4) with cancer incidence (all cancers, prostate, colorectal and lung cancer). Associations with cancer-related deaths were also explored.
A prospective cohort study involving community-dwelling men aged 70-89 years.
Thyroid hormones were measured in 3836 men between 2001 and 2004. Competing risks analyses were used to perform longitudinal analyses with results expressed as subhazard ratios (SHR). Outcomes were ascertained through electronic linkage until 20 June 2013.
Mean age was 77·0 ± 3·6 years. A total of 864 men developed cancers, and 506 experienced cancer-related deaths. A total of 340, 136 and 119 men developed prostate, colorectal and lung cancers, respectively. After adjustments, there were no associations between TSH and incidence of all cancers, prostate or lung cancer. Higher TSH was associated with increased colorectal cancer incidence (SHR = 1·19, 95% CI 1·00-1·42; P = 0·048 for every 1 SD increase in log TSH). This association was strengthened after excluding the first year of follow-up (SHR = 1·23, 95% CI 1·02-1·48, P = 0·028). FT4 was not associated with incidence of all cancers, prostate, colorectal or lung cancer. Thyroid hormones were not associated with cancer-related deaths.
In community-dwelling older men, FT4 was not associated with cancer incidence. Higher TSH is independently associated with increased incidence of colorectal cancer. Further investigation is warranted to determine whether a causal relationship exists.
甲状腺激素调节细胞存活和新陈代谢;然而,它们与癌症发病率和死亡率之间的关联尚未得到充分研究。
我们的目的是研究促甲状腺激素(TSH)和游离甲状腺素(FT4)与癌症发病率(所有癌症、前列腺癌、结直肠癌和肺癌)之间的关系。还探讨了与癌症相关死亡的关联。
一项针对70 - 89岁社区居住男性的前瞻性队列研究。
在2001年至2004年间对3836名男性进行了甲状腺激素测量。采用竞争风险分析进行纵向分析,结果以亚风险比(SHR)表示。通过电子链接确定结局直至2013年6月20日。
平均年龄为77.0±3.6岁。共有864名男性患癌,506名经历了癌症相关死亡。分别有340名、136名和119名男性患前列腺癌、结直肠癌和肺癌。调整后,TSH与所有癌症、前列腺癌或肺癌的发病率之间无关联。较高的TSH与结直肠癌发病率增加相关(SHR = 1.19,95%CI 1.00 - 1.42;log TSH每增加1个标准差,P = 0.048)。排除随访第一年之后,这种关联得到加强(SHR = 1.23,95%CI 1.02 - 1.48,P = 0.028)。FT4与所有癌症、前列腺癌、结直肠癌或肺癌的发病率均无关联。甲状腺激素与癌症相关死亡无关。
在社区居住的老年男性中,FT4与癌症发病率无关。较高的TSH独立地与结直肠癌发病率增加相关。有必要进一步研究以确定是否存在因果关系。